Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients.Study Design: Multicenter observati...
Similar Items
-
Massive Right Atrial Thrombosis: Are You Brave Enough to Start Anticoagulation? A Case Report
by: Marco Bergonti, et al.
Published: (2021-07-01) -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
by: Katleen de Gaetano Donati, et al.
Published: (2010-11-01) -
Further evidence that calcium, magnesium and seaweed mixtures reduce grapevine leaf stripe symptoms and increase grape yields
by: Francesco CALZARANO, et al.
Published: (2018-12-01) -
On Heat and Paper : From Hot Pressing to Impulse Technology
by: Lucisano, Marco Francesco Carlo
Published: (2002) -
Case Report: Pericardial Effusion Treated With Pericardiectomy Plus Right Atrial Mass Resection: A 2-Year Follow-Up of Cardiac Rosai-Dorfman Disease
by: Edoardo Conte, et al.
Published: (2021-05-01)